What is driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market?

The chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market is experiencing steady growth, fueled by increasing awareness of rare neurological disorders, the availability of advanced diagnostic tools, and expanding treatment options such as immunotherapies and stem cell therapies. Valued at USD 4.13 billion in 2024, the market is expected to rise at a CAGR of 6.90%, reaching USD 8.05 billion by 2034. Drivers include technological advancements in electrodiagnostic testing, the rising prevalence of neuropathic disorders in aging populations, and the increased adoption of plasma-derived and immunoglobulin-based therapies.

For more detailed insights into the evolving treatment landscape and market projections, readers can also explore the CIDP Therapeutics Market Size & Share Report, 2034, which provides a comprehensive analysis of trends, opportunities, and future growth drivers.

What is CIDP, and why is the treatment market expanding?

CIDP is a rare chronic neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to immune-mediated damage of the peripheral nerve’s myelin sheath. Unlike acute neuropathies, CIDP develops over weeks to months and requires long-term treatment to manage relapses and slow progression.

The treatment market is expanding because:

  • Improved early diagnosis through advanced testing methods (nerve conduction, EMG, CSF analysis).

  • Increased use of IVIG, corticosteroids, and plasma exchange as standard-of-care therapies.

  • Introduction of novel immunotherapies and stem cell treatments in research pipelines.

  • Rising neurology-focused investments and awareness campaigns.

  • Growing patient access to specialty neurological clinics and rehabilitation care.

Key Market Drivers

  • Increasing prevalence of autoimmune neuropathies, especially in aging populations.

  • R&D in immunotherapy and plasma-derived therapies to enhance long-term safety.

  • Global expansion of plasma collection and immunoglobulin supply chains.

  • Advancements in diagnosis, with electrodiagnostic testing improving disease detection accuracy.

  • Government support for orphan disease research and funding.

  • Integration of multidisciplinary approaches including physiotherapy, reducing disability progression.

Market Segmentation

Market Breakup by Therapeutic Method

  • Corticosteroids: Commonly prescribed to reduce inflammation, widely available and cost-effective.

  • Intravenous Immunoglobulin (IVIG): Gold-standard therapy, showing high efficacy in managing symptoms.

  • Plasma Exchange (Plasmapheresis): Used in severe cases, particularly when patients do not respond to other therapies.

  • Immunotherapy: Advanced biologics and monoclonal antibodies under clinical evaluation.

  • Stem Cell Transplant: Emerging treatment with potential curative outcomes, though still experimental.

  • Physical Therapy: Critical for long-term rehabilitation and improving mobility.

  • Others: Combination therapies tailored to patient-specific needs.

Market Breakup by Diagnosis

  • Electrodiagnostic Testing: Widely used to confirm conduction abnormalities.

  • Nerve Conduction Studies: Standard diagnostic tool for detecting demyelinating activity.

  • Electromyography (EMG): Supplements nerve conduction tests with muscle activity insights.

  • Spinal Fluid Analysis: Detects elevated protein levels without significant cellular abnormalities.

  • Others: Including nerve biopsies and blood-based biomarker testing.

Market Breakup by Route of Administration

  • Intravenous: Primarily for IVIG and plasma therapies.

  • Oral: For corticosteroids and select immunomodulatory drugs.

  • Others: Subcutaneous immunoglobulin therapies and emerging delivery mechanisms.

Market Breakup by End User

  • Hospitals: Largest consumer segment due to access to advanced infusion and neurology services.

  • Specialty Neurological Clinics: Growing adoption for chronic patient management and rehabilitation.

  • Research and Academic Laboratories: Crucial for drug discovery, clinical trials, and innovation.

Market Breakup by Region

  • North America: Largest share due to advanced healthcare infrastructure, availability of IVIG therapies, and high CIDP awareness.

  • Europe: Strong market growth supported by public healthcare systems and orphan drug designations.

  • Asia Pacific: Fastest-growing region, with expanding neurologist networks in China, Japan, and India.

  • Latin America: Emerging market with rising healthcare access and pharmaceutical investments.

  • Middle East and Africa: Gradual growth with improving neurology diagnostics and treatment facilities.

Explore the Green Frontier: Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
Access forecasts, trends, and key insights for smart decision-making—claim your free report.

Competitive Landscape

The CIDP treatment market is moderately consolidated with global pharmaceutical leaders investing in immunotherapy and next-gen biologics. Major companies include:

  • Grifols, S.A.

  • Octapharma AG

  • Baxter International Inc.

  • Pfizer Inc.

  • CSL Behring LLC

  • MedDay SA

  • Shire plc (now part of Takeda)

  • Takeda Pharmaceutical Company Limited

  • Teijin Limited

  • Momenta Pharmaceuticals, Inc.

They are prioritizing IVIG pipeline expansion, biologics development, plasma collection network improvements, and collaborations with neurological associations.

Emerging Trends in the CIDP Treatment Market

  • Shift toward subcutaneous immunoglobulin therapies (SCIG) for improved patient convenience.

  • Biologics and targeted immunotherapies in clinical trials.

  • Stem cell research advancing toward personalized regenerative medicine.

  • Digital and remote neurology care for long-term monitoring of chronic patients.

  • Government incentives for rare/orphan drugs, accelerating treatment innovation.

  • Integration of rehabilitation services into comprehensive treatment plans.

Future Outlook

By 2034, the global CIDP treatment market is projected to nearly double, reaching USD 8.05 billion. Growth will be supported by:

  • Expanding global access to immunoglobulin therapies.

  • Increased adoption of combination treatment approaches.

  • Asia Pacific’s rapid rise as a key growth hub due to improved healthcare investments.

  • A shift toward personalized and precision-based neurology care, integrating biomarkers for customized therapy.

The future landscape will likely see reduced long-term disability, better quality of life, and improved survival outcomes for CIDP patients as emerging therapies and cutting-edge biologics gain adoption.

Access More Reports

Advanced Wound Care Market

Artificial Insemination Market

Amyotrophic Lateral Sclerosis Market

Dementia Drugs Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com